

The consortium led by Universitätsklinikum Erlangen and the European Stroke Research Network for Hypothermia (EuroHYP), is to announce the launch of a clinical trial of unprecedented scale which will be rolled out across 25 countries in Europe to assess mild hypothermia as the most promising treatment for ischemic stroke.

The key officers in the project will be outlining the final details of the EUROHYP-1 trial, and the result of the submission for funding by the European Commission under the Seventh Framework Programme at a **PRESS CONFERENCE** on **March 19, 2012** in **Brussels, Belgium**.

ON THE PANEL:

- Prof. Stefan Schwab, Professor and Chair of the Department of Neurology at the Friedrich-Alexander-University Erlangen-Nürnberg, Germany; Coordinator of the EuroHYP-1 Consortium
- Dr. Malcolm Macleod, Senior Lecturer and Head of Experimental Neuroscience at the Centre for Clinical Brain Sciences at the University of Edinburgh, United Kingdom; EuroHYP-1 Scientific Liaison Officer
- Dr. Jesper Petersson, Head of Department and Associate Professor, Department of Neurology - Skåne University Hospital, Sweden; EuroHYP-1 Patient Liaison Officer
- Dr. Bart van der Worp, Department of Neurology, University Medical Centre Utrecht, The Netherlands; EuroHYP-1 Executive Committee Member

Journalists will have the opportunity to hear the latest on this promising project, find out the role each leading country will be taking in the research and ask questions also to the stroke researchers, patient groups and Small and Medium sized Enterprises involved in the trial, which will also be attending.

The EuroHYP-1 trial is a pan-European, open, randomised, phase III clinical trial which will assess the benefit of therapeutic cooling in adult patients with acute ischaemic stroke. In addition to efficacy and safety, the economic impact of therapeutic hypothermia will be also evaluated.

The EuroHYP consortium brings together leading European experts in statistical design and analysis, therapeutic hypothermia, imaging, health economics, ultrasound, biomarkers, and trial execution (implementation and monitoring) as well as European patient and family advocacy groups and Small and Medium-size Enterprises

NOTE TO EDITORS

The press conference will be followed by refreshments and the opportunity to continue the discussion in a convivial setting and engage in one-to-one dialogue with experts, patient representatives and other stakeholders in the trial such as SMEs developing the new technologies and processes necessary for the trial, which is expected to lead to significant spin offs in term of technological innovation and R&D capabilities

Information will be available for the press in French, English, German, Spanish and Italian.

When: Monday March 19, 2012, 10:30pm to 11:00pm CET

Where: Press Club Brussels Europe, Rue Froissart 95, 1040 Brussels, Belgium

INTERVIEWS, CONTACT AND REGISTRATION:

Roberta Bonometti, Press Officer

+44 7770 211955

roberta@bonometti.org

[www. Eurohyp.org](http://www.Eurohyp.org)